98%
921
2 minutes
20
Purpose: Predicting the malignancy of pure ground-glass nodules (GGNs) using CT is challenging. The optimal role of [F]FDG PET/CT in this context has not been clarified. We compared the performance of [F]FDG PET/CT in evaluating GGNs for predicting invasive adenocarcinomas (IACs) with CT.
Methods: From June 2012 to December 2020, we retrospectively enrolled patients with pure GGNs on CT who underwent [F]FDG PET/CT within 90 days. Overall, 38 patients with 40 ≥ 1-cm GGNs were pathologically confirmed. CT images were analyzed for size, attenuation, uniformity, shape, margin, tumor-lung interface, and internal/surrounding characteristics. Visual [F]FDG positivity, maximum standardized uptake value (SUV), and tissue fraction-corrected SUV (SUV) were evaluated on PET/CT.
Results: The histopathology of the 40 GGNs were: 25 IACs (62.5%), 9 minimally invasive adenocarcinomas (MIA, 22.5%), and 6 adenocarcinomas in situ (AIS, 15.0%). No significant differences were found in CT findings according to histopathology, whereas visual [F]FDG positivity, SUV, and SUV were significantly different (P=0.001, 0.033, and 0.018, respectively). The size, visual [F]FDG positivity, SUV, and SUV showed significant diagnostic performance to predict IACs (area under the curve=0.693, 0.773, 0.717, and 0.723, respectively; P=0.029, 0.001, 0.018, and 0.013, respectively). In the multivariate logistic regression analysis, visual [F]FDG positivity discriminated IACs among GGNs among various CT and PET findings (P=0.008).
Conclusions: [F]FDG PET/CT demonstrated superior diagnostic performance compared to CT in differentiating IAC from AIS/MIA among pure GGNs, thus it has the potential to guide the proper management of patients with pure GGNs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12149-024-01944-2 | DOI Listing |
J Cereb Blood Flow Metab
September 2025
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Preclinical PET studies offer the opportunity to elucidate molecular mechanisms underlying early neurodevelopment with minimal invasiveness. We demonstrated the feasibility of fetal brain PET in four pregnant rats ( = 42 fetuses). [F]FDG uptake in rat fetuses was readily visualized by PET imaging.
View Article and Find Full Text PDFNucl Med Biol
September 2025
Department of Nuclear Medicine, Hannover Medical School, Germany. Electronic address:
Purpose: The liver-brain axis regulates metabolic homeostasis, with glucose metabolism playing a key role. Liver dysfunction, such as fibrosis, may impact brain metabolism and consequently, brain function. Positron emission tomography (PET) imaging provides a non-invasive approach to study glucose metabolism in both organs.
View Article and Find Full Text PDFCancer Immunol Immunother
September 2025
Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, CHUV/UNIL, 1011, Lausanne, Switzerland.
Background: Immunotherapy is a mainstay in the treatment of patients with advanced melanoma. Yet, resistance mechanisms exist, and tumour-associated macrophages (TAMs), particularly the M2-like phenotype, are associated with poorer outcomes, with CD206 serving as their specific marker. We present the first human SPECT/CT study to visualize CD206 + TAMs in patients undergoing immunotherapy and compare the findings to clinical outcomes (NCT04663126).
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
September 2025
Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Purpose: Tebentafusp has emerged as the first systemic therapy to significantly prolong survival in treatment-naïve HLA-A*02:01 + patients with unresectable or metastatic uveal melanoma (mUM). Notably, a survival benefit has been observed even in the absence of radiographic response. This study aims to investigate the feasibility and prognostic value of artificial intelligence (AI)-assisted quantification and metabolic response assessment of [F]FDG long axial field-of-view (LAFOV) PET/CT in mUM patients undergoing tebentafusp therapy.
View Article and Find Full Text PDFMol Imaging Radionucl Ther
September 2025
University Clinical Center of Serbia, Center for Nuclear Medicine with PET, Belgrade, Serbia.
Fluorine-fluorocholine (F-FCH) is a radiopharmaceutical used in primary hyperparathyroidism. The data about its utility in malignancies other than prostate and hepatocellular carcinoma is limited. We present the case of a patient who was referred for F-FCH positron emission tomography/computed tomography (PET/CT) due to the persistently elevated parathormone and calcium levels following total thyroidectomy with left lower parathyroidectomy for parathyroid carcinoma (PTC).
View Article and Find Full Text PDF